X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aim to support the development of ATH-063, which is a small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with inflammatory bowel disease, Crohn Disease, Ulcerative Colitis.
Lead Product(s): ATH-063
Therapeutic Area: Gastroenterology Product Name: ATH-063
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 16, 2024
Details:
ATH-063 is a first-in-class, oral, small molecule, genomic regulator acts both by suppressing pro-inflammatory responses and inducing direct mucosal healing, being developed for inflammatory bowel diseases, other autoimmune diseases and solid cancers.
Lead Product(s): ATH-063
Therapeutic Area: Gastroenterology Product Name: ATH-063
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Athos to perform molecular analysis of biopsies from de-identified Inflammatory Bowel Disease patient having ATH-63, samples from Lahey Hospital & Medical Center based in Burlington, Massachusetts.
Lead Product(s): ATH-63
Therapeutic Area: Gastroenterology Product Name: ATH-63
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lahey Hospital & Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 11, 2022
Details:
The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: FYB202
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Formycon
Deal Size: $720.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
